BNIP3L and astrocytoma (excluding glioblastoma): In terms of clinical outcome, a significant difference in Ki-67 percentage between Nix (+) and Nix (−) patients was found only in Grade II astrocytoma (p = 0.037), which indicated a minor tumor invasion for NIX (+) patients and supported the tumor-suppressor role of the NIX gene.